title: Neopterin, soluble IL-2 receptor and IL-6 secretion during IL-2 cancer immunotherapy: prognostic significance in relation to IL-12 variations.
authors.forename: P
authors.initials: P
authors.lastname: Lissoni
authors.forename: S
authors.initials: S
authors.lastname: Barni
authors.forename: G
authors.initials: G
authors.lastname: Di Felice
authors.forename: F
authors.initials: F
authors.lastname: Majorca
authors.forename: L
authors.initials: L
authors.lastname: Fumagalli
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007167:Immunotherapy; D018664:Interleukin-12 / Q000097:blood*; D007376:Interleukin-2 / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000378:metabolism*; D007680:Kidney Neoplasms / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D019798:Neopterin / Q000097:blood*; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000097:blood*; D012995:Solubility
chemical_list: D000276:Adjuvants, Immunologic; D007376:Interleukin-2; D015850:Interleukin-6; D015375:Receptors, Interleukin-2; D018664:Interleukin-12; D019798:Neopterin